{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=10&state=Oregon", "query": { "state": "Oregon", "city": "Portland", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 9360, "total_pages": 936, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=11&state=Oregon&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=9&state=Oregon&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T08:53:42.569Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04003610", "title": "Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-05-14", "completion_date": "2021-04-18", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 13, "location_summary": "Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003610" }, { "nct_id": "NCT03761017", "title": "MGD019 DART® Protein in Unresectable/Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Non Small Cell Lung Cancer", "Prostate Cancer Metastatic", "Cutaneous Melanoma", "Colorectal Cancer", "Advanced Cancer", "Solid Tumor, Adult" ], "interventions": [ { "name": "Lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2018-12-12", "completion_date": "2025-01-27", "has_results": false, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 17, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 11 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761017" }, { "nct_id": "NCT00778960", "title": "Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Post-Traumatic Stress Disorders" ], "interventions": [ { "name": "Slow Breathing", "type": "BEHAVIORAL" }, { "name": "Meditation", "type": "BEHAVIORAL" }, { "name": "Meditation and slow breathing", "type": "BEHAVIORAL" }, { "name": "Sitting Quietly", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 102, "start_date": "2009-01", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-07-13", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778960" }, { "nct_id": "NCT00047125", "title": "Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma of Unknown Primary" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 600, "start_date": "2002-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-07-09", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 237, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047125" }, { "nct_id": "NCT00109850", "title": "S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-05", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 132, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109850" }, { "nct_id": "NCT02445391", "title": "Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Negative", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2015-10-20", "completion_date": "2031-03-29", "has_results": true, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 1023, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02445391" }, { "nct_id": "NCT01030874", "title": "Orthostatic Hypotension Treatment on Rehab Unit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Orthostatic Hypotension", "Falls" ], "interventions": [ { "name": "Medication review", "type": "OTHER" }, { "name": "Nutrition/Salt intake", "type": "OTHER" }, { "name": "Education", "type": "OTHER" }, { "name": "Exercise", "type": "OTHER" }, { "name": "Drug Recommendations", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 356, "start_date": "2011-10", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2021-07-01", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030874" }, { "nct_id": "NCT01715818", "title": "A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease, Diabetes Mellitus Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "aleglitazar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1999, "start_date": "2012-12", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 143, "location_summary": "Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cudahy", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01715818" }, { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT03345082", "title": "A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "OPT-302", "type": "BIOLOGICAL" }, { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "sham intravitreal injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Opthea Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 366, "start_date": "2017-11-06", "completion_date": "2019-05-14", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-10-31T08:53:42.569Z", "location_count": 55, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345082" } ] }